33 results about "Cartilage Matrix" patented technology

A method for modeling temporomandibular joint osteoarthritis, 6-week-old rats are selected, the rats are confirmed to have entered an anesthetized state before surgery, the rat's mandibular incisors are first checked and confirmed to be normal, the first arm of the device is sleeved on one side of the mandibular incisor, and the palatal side of the maxillary incisor is made to touch the slope surface of the second arm of the device, the device is checked and confirmed to not affect the rat's mandibular movement and occlusion, not significantly raise the bite, have no early contact, and the upper and lower jaw relationship is relatively stable; the device and the mandibular incisor sleeved with the device are fixed; then the rat is put back into the cage, and soft food or powdered feed is given after waking up; the device is removed after being fed for 8 weeks or more. It is verified that the condylar process of the rat changes significantly, the overall condylar process is significantly reduced, the subchondral bone is destroyed, and the expression of the cartilage matrix is also reduced. Thus, a TMJOA rat model exhibiting mandibular retrusion is formed.

An object is to provide a joint function-improving composition which is useful for prevention or treatment of various arthropathies such as osteoarthritis including knee osteoarthritis as a typical example and rheumatoid arthritis because the composition has an action of promoting growth of chondrocytes and an action of suppressing the production of an inflammation factor, a cartilage matrix degradation factor, a pain factor or a neuronal outgrowth factor by synoviocytes and to provide a joint function-improving product containing the composition such as a food or a drink, feed and a medicine. A joint function-improving composition containing bacterial cells and / or a culture of a bacterium belonging to genera Lactobacillus, Lactococcus, Streptococcus or Bifidobacterium and a joint function-improving agent, a joint function-improving food or drink, a joint function-improving nutritional composition, joint function-improving feed or a joint function-improving pharmaceutical agent which is characterized by containing the joint function-improving composition.

The present disclosure relates to a method of treating arthritis by targeting Tankyrase. The methods according to the present disclosure can be advantageously used for regeneration of cartilage tissue and for treating osteoarthritis by maximizing the matrix synthesis in cartilage by inhibition of Tankyrase and regulation of other proteins related therewith.

The application relates to an anti-inflammatory and cartilage regeneration promoting material, a preparation method and application thereof, and belongs to the technical field of biomedical materials. The anti-inflammatory and cartilage regeneration promoting material comprises a PLGA (50:50) polymer material, and a huperzine A derivative dimer loaded on the PLGA (50:50) polymer material through 3D printing. The application also provides the use of the anti-inflammatory and cartilage regeneration promoting material in the preparation of anti-inflammatory, cartilage protection or cartilage regeneration promoting drugs. The PLGA / A10E scaffold has good biocompatibility, the PLGA / A10E scaffold degradation release liquid can effectively promote the differentiation of cartilage precursor cells into cartilage, and increase the formation of cartilage collagen matrix and cartilage proteoglycan. The in-vitro degradation liquid of the PLGA / A10E scaffold can promote the expression of SOX9 under non-inflammatory conditions; under LPS-mediated inflammatory conditions, the expression of MMP-13 can be inhibited, thereby promoting the synthesis of cartilage matrix and inhibiting the degradation of cartilage matrix.

A pharmaceutical compositions includes GLP-1 and GLP-1 analogues inducing an anabolic stimulation of chondrocytes and a decreasing in chondrocyte catabolic including a decrease in cartilage matrix loss and cartilage degeneration for use in the treatment of cartilage disease. The composition induces cartilage regeneration and anabolic stimulation of chondrocytes, including chondrocyte proliferation and / or stem cell differentiation into chondrocytes.

The invention discloses a mesenchymal stem cell compound preparation for treating cartilage injury, and belongs to the technical field of cell biology. The composite preparation consists of human umbilical cord mesenchymal stem cells (hUC-MSC) subjected to specific pretreatment and a pharmaceutical carrier. The pretreatment method sequentially comprises the following steps: carrying out low-oxygen pretreatment on the hUC-MSC; then, carrying out pretreatment on a ferroptosis inhibitor Ferrostatin-1 under a low-oxygen condition; and finally, carrying out icariin pretreatment under a normal oxygen condition. The unique triple pretreatment strategy generates a remarkable synergistic effect, and can greatly improve the survival rate and the function maintenance capability of the hUC-MSC in the cartilage injury inflammatory microenvironment. Experimental results prove that the preparation can significantly inhibit collagen degradation and promote cartilage matrix regeneration, and the treatment efficiency of stem cell transplantation and the repair effect of cartilage injury are effectively improved.

The invention provides a tribenzoyl substituted vakognavine type diterpenoid alkaloid, a preparation method and application of the tribenzoyl substituted vakognavine type diterpenoid alkaloid, and a pharmaceutical composition. After rats are treated by the tribenzoyl substituted vakognavine type diterpenoid alkaloid provided by the invention, the quality reduction trend is obviously relieved, and the foot swelling degree and the arthritis score are obviously reduced; bone loss induced by AIA can be effectively inhibited, and the structural integrity of bone trabecula is protected; cartilage matrix degradation can be inhibited, and cartilage erosion damage is relieved; the anti-inflammatory effect can be achieved by inhibiting the expression of key proinflammatory factors in bone tissues.

This invention provides a stress-triggered selective targeting hydrogel microsphere, its preparation method, and its application, belonging to the field of biomedical technology. The core of this invention is the "stress-triggered charge reversal" mechanism. It utilizes the interaction between weakly cross-linked disulfide bonds broken under stress and "charge reversal" messenger molecules to achieve "charge reversal" of nanoparticles under stress. A dual-network hydrogel microsphere system is prepared using microfluidic technology to achieve bearing lubrication and stress relaxation within the joint cavity. Stress-triggered charge reversal is achieved at stress-overloaded cartilage lesions, imparting a positive charge to the drug-loaded nanoparticles within the hydrogel microspheres. This significantly enhances the ability of the drug-loaded nanoparticles to penetrate deep into the cartilage matrix and target chondrocytes for drug release under the guidance of the charge. This enables the selective and targeted release of appropriate drug concentrations to deep-seated chondrocytes in pathological microenvironments induced by different stress intensities, achieving highly effective and low-toxicity treatment of osteoarthritis.

The invention belongs to the technical field of biological medicine, and particularly relates to a preparation method and application of an amniotic fluid active complex. According to the method, inherent physical and chemical differences of different components in amniotic fluid are utilized, through a series of physical steps, the components are firstly and mildly grouped and enriched according to categories, and then the components are guided to be self-assembled again under controllable conditions to form a composite particle with a compact structure. The natural aggregation state of active ingredients in a living body before secretion or action is simulated, so that the multi-element active ingredients which naturally coexist and interact in amniotic fluid are efficiently captured and transferred as a complete functional unit, the natural ingredient spectrum is not damaged, and the original advanced structure and function are not lost. The invention provides application of an amniotic fluid active complex (RSC) in treating or preventing joint diseases or symptoms. The RSC has obvious effects in promoting cartilage matrix synthesis, inhibiting moderate and mild osteoarthritis and relieving pain.

This invention discloses a chitosan-based lidocaine formulation for intra-articular use and its preparation method. Belonging to the field of pharmaceutical formulation technology, the formulation is prepared from chitosan, carboxymethyl chitosan, lidocaine, chitosan-PNIPAM microspheres, sulfated trehalose, and excipients. The chitosan-PNIPAM used in this invention exhibits dual temperature and pH response. With temperature changes, PNIPAM possesses both hydrophobic contractile and hydrophilic swelling states, thereby controlling the lidocaine release rate. Simultaneously, when the pH decreases, chitosan repels PNIPAM, further disintegrating the microspheres to release the drug, thus achieving targeted analgesia. Sulfated trehalose, as a cartilage matrix synthesis promoter, can activate intracellular signaling pathways in chondrocytes, promoting the synthesis of type II collagen and proteoglycans. Simultaneously, the sulfate groups can form electrostatic complexes with the amino groups of chitosan, enhancing drug retention. The formulation of this invention can inhibit synovial cells, release cytokines, and synergistically with carboxymethyl chitosan, increase the inhibition rate of inflammatory factors by 40%-50%.

The invention provides Haitesan type diterpenoid alkaloid as well as a preparation method, application and a pharmaceutical composition thereof. After rats are treated by the Haitesan diterpenoid alkaloid provided by the invention, the quality reduction trend is obviously relieved, and the foot swelling degree and the arthritis score are obviously reduced; bone loss induced by AIA can be effectively inhibited, and the structural integrity of bone trabecula is protected; cartilage matrix degradation can be inhibited, and cartilage erosion damage is relieved; the anti-inflammatory effect can be achieved by inhibiting the expression of key proinflammatory factors in bone tissues.

The invention provides diterpenoid alkaloid in delphinium delphinium as well as a preparation method, application and a pharmaceutical composition of the diterpenoid alkaloid. After rats are treated by diterpenoid alkaloid in delphinium delphinium provided by the invention, the quality reduction trend is obviously relieved, and the foot swelling degree and the arthritis score are obviously reduced; bone loss induced by AIA can be effectively inhibited, and the structural integrity of bone trabecula is protected; cartilage matrix degradation can be inhibited, and cartilage erosion damage is relieved; the anti-inflammatory effect can be achieved by inhibiting the expression of key proinflammatory factors in bone tissues.

The invention provides a composition for improving bone joints and promoting bone health as well as a preparation method and application thereof, and relates to the technical field of compositions. The composition is prepared from N-acetylglucosamine and a turmeric extract. The composition can improve the differentiation activity of cartilage precursor cells, effectively promote synthesis of cartilage matrixes, increase the structural construction ability of cartilage tissues, reverse expression down-regulation of cartilage synthesis markers, down-regulate abnormally high expression of cartilage decomposition markers and maintain metabolic balance of cartilage synthesis and decomposition, and has the effects of improving the cartilage tissue differentiation activity and improving the cartilage tissue differentiation activity. Abnormal high secretion of tumor necrosis factors alpha and interleukin 6 in LPS-induced cartilage cells is reduced, and the effects of resisting inflammation, resisting cartilage degradation and maintaining cartilage metabolism balance are achieved.

The invention provides C20 type diterpenoid alkaloid, a preparation method and application thereof and a pharmaceutical composition. After rats are treated by the C20 type diterpenoid alkaloid provided by the invention, the quality reduction trend is obviously relieved, and the foot swelling degree and the arthritis score are obviously reduced; bone loss induced by AIA can be effectively inhibited, and the structural integrity of bone trabecula is protected; cartilage matrix degradation can be inhibited, and cartilage erosion damage is relieved; the anti-inflammatory effect can be achieved by inhibiting the expression of key proinflammatory factors in bone tissues.

This specification discloses an oligonucleotide capable of specifically hybridizing with miR-204, and compositions comprising the oligonucleotide for improving, preventing, or treating osteoarthritis. In one aspect, the oligonucleotide is designed with an optimized structure for miR-204 degradation and formulation stability, effectively blocking pathophysiological processes of osteoarthritis such as decreased cartilage matrix synthesis and increased inflammatory response, thereby preventing or treating osteoarthritis. Furthermore, it exhibits excellent delivery capability to chondrocytes and stable residence within tissues, thus possessing structural advantages for achieving long-term, sustained therapeutic effects. It also has low immunogenicity and toxicity, possessing safety suitable for use in pharmaceutical compositions. In addition, it effectively inhibits miR-204 in canine chondrocytes, therefore it can be used in animal therapeutics and / or feed compositions, etc.

The invention provides tetrabenzoyl substituted vakognavine type diterpenoid alkaloid as well as a preparation method, application and a pharmaceutical composition of the tetrabenzoyl substituted vakognavine type diterpenoid alkaloid. After rats are treated by the tetrabenzoyl substituted vakognavine type diterpenoid alkaloid provided by the invention, the quality reduction trend is obviously relieved, and the foot swelling degree and the arthritis score are obviously reduced; bone loss induced by AIA can be effectively inhibited, and the structural integrity of bone trabecula is protected; cartilage matrix degradation can be inhibited, and cartilage erosion damage is relieved; the anti-inflammatory effect can be achieved by inhibiting the expression of key proinflammatory factors in bone tissues.

The invention discloses an external-use compound formula for assisting skeletal development and cartilage health of teenagers, and belongs to the technical field of external-use health-care preparations. According to the formula, yak bone marrow peptide, glucosamine hydrochloride, chondroitin sulfate and bone collagen peptide serve as core active ingredients, rose hip oil is matched to serve as a transdermal penetration enhancing component, transdermal absorption of the active ingredients is achieved through reasonable matching, osteoblast metabolism of teenagers (6-18 years old) can be promoted in a targeted mode, the bone mineral density can be increased, and the effect of preventing and treating osteoporosis is achieved. Meanwhile, cartilage matrix synthesis is strengthened, cartilage injury is reduced, and the problem that external health care products are deficient in the teenager skeletal cartilage development stage is solved. According to the technical verification of the Zhejiang traditional Chinese medicine university medicine college modern medicine research center, the formula is high in safety and excellent in transdermal efficiency, adapts to teenager skin barrier characteristics, and has remarkable application value in the fields of teenager skeletal development and cartilage health maintenance.

The invention relates to liquid modified milk and a preparation method thereof, the liquid modified milk comprises animal milk, glucosamine hydrochloride, calcium beta-hydroxy-beta-methylbutyrate and cordyceps militaris extract, the cordyceps militaris extract contains cordycepin and adenosine, the cordycepin content in the liquid modified milk is greater than or equal to 1.6 mg / 100mL, and the adenosine content in the liquid modified milk is greater than or equal to 0.6 mg / 100mL. According to the modified milk provided by the invention, cordycepin enhances the biosynthesis and energy supply capability of mitochondria by activating related signal channels, and provides an energy basis for the GaHMB to play a role, so that the synthesis efficiency of muscle protein is improved; adenosine and glucosamine have a synergistic effect, so that conduction of inflammation-related signals can be blocked, and decomposition of cartilage matrixes is reduced; meanwhile, glucosamine is used as a glycosaminoglycan precursor, under the action of a signal channel regulated and controlled by adenosine, the synthesis efficiency of cartilage tissue can be remarkably stimulated, the utilization efficiency of sugar is improved, and finally triple synergistic intervention of muscle-joint-metabolism is achieved.

The present application belongs to the technical field of microbial fermentation, and particularly relates to Lactobacillus rhamnosus for maintaining bone health and improving local inflammation of joints, postbiotic and application thereof. The present application prepares a postbiotic product by fermenting and culturing probiotic NKU ML1-2. The results of examples prove that the postbiotic drug can enhance the antioxidant capacity of chondrocytes and osteoblasts, promote the synthesis of anti-inflammatory factors and cartilage matrix (type II collagen and proteoglycan), has the potential to reduce local oxidative stress and inflammatory response of joints, relieve joint inflammation, and delay cartilage destruction. The postbiotic drug prepared by the present application has high safety and good stability, and can be applied to the preparation of drugs for preventing and / or treating osteoarthritis; the postbiotic drug can also be used to promote bone health, enhance the antioxidant capacity of osteoblasts and / or chondrocytes, promote osteoblast activity and / or promote calcium absorption and fixation, and provides a new solution for joint health management.

The invention discloses a human mesenchymal stem cell preparation activated by specific immune pretreatment and application thereof, and the application is characterized in that human mesenchymal stem cells (hAMSCs) and autologous human peripheral blood lymphocytes are co-cultured and pretreated according to a specific ratio (such as 100: 1), and then are applied to a knee osteoarthritis model through intra-articular injection. The synergistic treatment effect which is obviously superior to that of the unpretreated hAMSCs can be generated; the Co-hAMSCs show a unique in-vivo action mode, the survival time of the Co-hAMSCs at the local part of the joint is shorter than that of common hAMSCs, but the Co-hAMSCs can quickly relieve pain in the early treatment stage, improve the joint function and lower local inflammation; the cartilage repair and regeneration can be more effectively promoted for a long time, and the specific expression is as follows: the cartilage histological score is obviously improved, the content of cartilage matrix glycosaminoglycans (especially middle and deep layers) is increased, and the repaired tissue is guided to be transformed to a hyaline cartilage sample phenotype with high expression of type II collagen and low expression of type I collagen, so that the cartilage repair and regeneration can be more effectively promoted. And inflammatory factor balance of local joints and the whole body can be synchronously adjusted.

The invention provides vakognavine type diterpenoid alkaloid, a preparation method and application of the vakognavine type diterpenoid alkaloid, and a pharmaceutical composition. After rats are treated by the vakognavine type diterpenoid alkaloid provided by the invention, the quality reduction trend is obviously relieved, and the foot swelling degree and the arthritis score are obviously reduced; bone loss induced by AIA can be effectively inhibited, and the structural integrity of bone trabecula is protected; cartilage matrix degradation can be inhibited, and cartilage erosion damage is relieved; the anti-inflammatory effect can be achieved by inhibiting the expression of key proinflammatory factors in bone tissues.

The present specification provides an oligonucleotide specifically hybridized with miR-204, and a composition for alleviating, preventing or treating osteoarthritis, comprising same. The oligonucleotide according to one aspect of the present invention is designed to have a structure in which miR-204 degradation efficacy and formulation stability are optimized, and effectively blocks pathophysiological processes of osteoarthritis such as decreased cartilage matrix synthesis and increased inflammatory response, and thus is useful for preventing or treating osteoarthritis, and exhibits excellent delivery ability to chondrocytes and stable retention characteristics in tissues, thereby providing a structural advantage of implementing a long-lasting therapeutic effect and safety suitable for use as a pharmaceutical composition since the immunogenicity-inducing potential and toxicity are low, and enabling miR-204 in canine-derived chondrocytes to be effectively inhibited such that the oligonucleotide can be used as an animal therapeutic agent and / or a feed composition.

The present invention relates to a composition for disease-modifying treatment of osteoarthritis. More specifically, the present invention relates to a composition for treating osteoarthritis and a method for treating osteoarthritis by using same, the composition comprising human umbilical cord blood-derived mesenchymal stem cells (hUCB-MSCs) and an acellular cartilage matrix.

This invention relates to the field of biomedical materials technology, specifically to a decellularized matrix microparticle-based ink for extrusion 3D printing and its preparation method. The key technical points are: dispersing decellularized matrix microparticles (dECM-MPs) in a metal ion solution for ion adsorption; the dECM-MPs include cartilage matrix microparticles (DCM-MPs) or bone matrix microparticles (DBM-MPs); then, without damaging the structure and composition of the dECM-MPs, forming a hydrogel microlayer in situ on the surface of the dECM-MPs through interfacial ion diffusion crosslinking; centrifuging the dECM-MPs encapsulated in the hydrogel microlayer to obtain an ink suitable for extrusion 3D printing; and using this 3D printing ink to print and then fixing it with ultraviolet light to obtain a 3D printed implant. The particulate ink prepared by this invention has good printability, overcoming the significant challenge of 3D printing hard tissue microparticles.

This invention belongs to the field of nutritional composition technology, specifically relating to a composition, composition formulation, preparation method, application, and product for improving bone health. This invention provides a composition composed of N-acetylglucosamine and 3-O-acetyl-11-keto-β-boswellic acid. The composition and formulation of this invention can promote the differentiation of chondrocyte precursor cells into mature chondrocytes, promote cartilage matrix synthesis, significantly inhibit TNF-α and MMP13 expression, and upregulate COL2A1 expression, with effects superior to single components and traditional combinations. The ingredients are natural and safe, biocompatible, and have no significant toxicity, making them suitable for people with joint noise, joint pain, osteoarthritis, and joint degeneration. Simultaneously, they can improve bone density, promote bone growth and development, and improve bone health. The preparation process is simple and low-cost, and it can be formulated into various dosage forms such as food, health products, and pharmaceuticals, offering flexible applications and combining preventative and therapeutic value.

The invention belongs to the technical field of cartilage repair materials, and particularly relates to a repair material for promoting cartilage regeneration and a preparation method and application thereof. The invention discloses a complex for promoting cartilage regeneration. The complex comprises nerve cells capable of secreting chondroitin sulfate. According to the hydrogel-loaded nerve cell complex capable of secreting chondroitin sulfate, the cells are fixed through the three-dimensional scaffold effect of the hydrogel, the cartilage matrix microenvironment is simulated, mechanical support is provided for the defect, and the advantage that the nerve cells secrete chondroitin sulfate is combined; the problems of limited tissue source, low tissue integration degree, insufficient generation of transparent cartilage and the like in the existing cartilage repair technology are solved.

The invention discloses a parent osteoarthritis intervention target based on an INSL3 / RXFP2 signal channel and application of the parent osteoarthritis intervention target. The pregestation caffeine exposure of the male body has obvious influence on the cartilage development of the male offspring, and the susceptibility of osteoarthritis is increased. Through screening and verification, INSL3 secreted by testicular interstitial cells plays a key role in the parent osteoarthritis, and cAMP / PKA / CREB signal channels are reduced by locally knocking out cartilage RXFP2 or inhibiting combination of INSL3 and RXFP2, so that synthesis and development of cartilage matrixes are inhibited. And the exogenous recombinant INSL3 protein is injected into the knee joint cavity, so that the cartilage dysplasia caused by pregestation caffeine exposure of the parent can be obviously improved. The invention discloses a key effect of an INSL3 / RXFP2 signal channel in regulation and control of cartilage matrix synthesis, and provides a new biological basis and an early prevention and treatment strategy for targeted therapy of osteoarthritis.

The application relates to the technical field of biological medicine, in particular to an engineered mesenchymal stem cell sphere exosome and a preparation method and application thereof. The method comprises the following steps: O-GlcNAc glycosylation modification is performed on mesenchymal stem cells to obtain O-GlcNAc glycosylation modified mesenchymal stem cells; the mesenchymal stem cells are subjected to sphere formation culture to form mesenchymal stem cell spheres; and three-dimensional culture is performed to make the mesenchymal stem cell spheres secrete exosomes containing hsa-miR-423-3p. The exosomes can efficiently deliver hsa-miR-423-3p to target cells, activate a mitochondrial autophagy pathway, selectively remove damaged mitochondria, thereby block ROS excessive release, maintain the level of GSH, SOD and other antioxidant substances, reduce oxidative stress damage, and finally promote chondrocyte survival and cartilage matrix synthesis.

The invention provides an intelligent drug delivery system for treating osteoarthritis as well as a preparation method and application thereof, the intelligent drug delivery system is a drug-loaded micelle of which the surface is covalently coupled with a virus glycoprotein mimic peptide, and the hydrodynamic diameter is 16 + / -5 nm; the sequence of the mimic peptide comprises a type II collagen adhesion domain and a matrix metalloproteinase 13 specific lysis domain, and the mimic peptide can simulate a dual action mechanism of a virus: firstly, the mimic peptide is non-specifically adhered to a cartilage matrix to realize long-acting retention, and then the mimic peptide is specifically activated in a microenvironment in which pathological cells overexpress MMP13, a cell penetrating peptide is exposed, and efficient intracellular delivery of a drug is driven. The technical bottlenecks of short drug residence time, poor cartilage penetrability and lack of lesion cell targeting in the traditional treatment method are solved, the breakthrough from cartilage targeting to precise lesion cartilage cell targeting is realized, cartilage degeneration can be obviously delayed, symptoms can be improved, and excellent curative effects and clinical transformation prospects are shown.